The first clinical trials of Mediator kinase inhibitors have been initiated in estrogen-receptor positive breast cancers (ClinicalTrials.gov Identifier: NCT03065010) and acute myeloid leukemia (AML) (ClinicalTrials.gov Identifier: NCT04021368). This evidence concerns the gene ESR1 and breast cancer.